{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:45:01Z","timestamp":1779248701828,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118667","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:40:20Z","timestamp":1761716420000},"page":"118667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anti-inflammatory therapies from bedside to bench: Frameworks to support preclinical development"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-9721","authenticated-orcid":false,"given":"Cristina","family":"Cigana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Gugliandolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"De Fino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-7669","authenticated-orcid":false,"given":"Alessandra","family":"Bragonzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118667_bib1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3389\/fphar.2020.01096","article-title":"Novel anti-inflammatory approaches for cystic fibrosis lung disease: identification of molecular targets and design of innovative therapies","volume":"11","author":"Mitri","year":"2020","journal-title":"Front. Pharm."},{"issue":"18","key":"10.1016\/j.biopha.2025.118667_bib2","first-page":"1","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2025.118667_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02133-2017","article-title":"Optimising experimental research in respiratory diseases: an ERS statement","volume":"51","author":"Bonniaud","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2025.118667_bib4","series-title":"Lost in Translation \u2013 The Challenges with the Use of Animal Models in Translational Research","author":"Carini","year":"2019"},{"issue":"3","key":"10.1016\/j.biopha.2025.118667_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118667_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.576293","article-title":"Designing clinical trials for anti-inflammatory therapies in cystic fibrosis","volume":"11","author":"Perrem","year":"2020","journal-title":"Front. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2025.118667_bib7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118667_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1183\/09031936.00018908","article-title":"Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction","volume":"31","author":"Chung","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.biopha.2025.118667_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/thoraxjnl-2013-203204","article-title":"Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications","volume":"68","author":"Cohen-Cymberknoh","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2025.118667_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.794854","article-title":"Editorial: novel anti-inflammatory approaches for cystic fibrosis lung disease: identification of molecular targets and design of innovative therapies","volume":"12","author":"Ribeiro","year":"2021","journal-title":"Front. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118667_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2013.10.007","article-title":"BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs","volume":"13","author":"Doring","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.biopha.2025.118667_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"17","key":"10.1016\/j.biopha.2025.118667_bib13","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2025.118667_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947359","article-title":"Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: serial upper airway sampling by nasal lavage","volume":"13","author":"Erdmann","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118667_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008439","article-title":"Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection","volume":"4","author":"Cigana","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2025.118667_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02456-2018","article-title":"Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa","volume":"55","author":"Cigana","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.biopha.2025.118667_bib17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ijmm.2010.08.012","article-title":"Murine models of acute and chronic lung infection with cystic fibrosis pathogens","volume":"300","author":"Bragonzi","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"issue":"85","key":"10.1016\/j.biopha.2025.118667_bib18","doi-asserted-by":"crossref","DOI":"10.3791\/51019-v","article-title":"Long term chronic Pseudomonas aeruginosa airway infection in mice","author":"Facchini","year":"2014","journal-title":"J. Vis. Exp."},{"issue":"4","key":"10.1016\/j.biopha.2025.118667_bib19","first-page":"939","article-title":"Cystic fibrosis lung inflammation: early, sustained, and severe","volume":"151","author":"Cantin","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6 Pt 1","key":"10.1016\/j.biopha.2025.118667_bib20","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1164\/ajrccm.152.6.8520783","article-title":"Inflammatory cytokines in cystic fibrosis lungs","volume":"152","author":"Bonfield","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118667_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2022.08.005","article-title":"Beta-sitosterol ameliorates inflammation and Pseudomonas aeruginosa lung infection in a mouse model","volume":"22","author":"Rossi","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2025.118667_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175349","article-title":"Efficacy of selective histone deacetylase 6 inhibition in mouse models of Pseudomonas aeruginosa infection: a new glimpse for reducing inflammation and infection in cystic fibrosis","volume":"936","author":"Brindisi","year":"2022","journal-title":"Eur. J. Pharm."},{"issue":"22","key":"10.1016\/j.biopha.2025.118667_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214483","article-title":"New TMA (4,6,4\u2032-trimethyl angelicin) analogues as anti-inflammatory agents in the treatment of cystic fibrosis lung disease","volume":"23","author":"Tupini","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118667_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01293-2021","article-title":"R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease","volume":"59","author":"Rigauts","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2025.118667_bib25","article-title":"The vagus nerve-dependent lung-brain axis mediates brain demyelination following acute lung injury","volume":"44","author":"Xu","year":"2025","journal-title":"Brain Behav. Immun. Health"},{"issue":"6","key":"10.1016\/j.biopha.2025.118667_bib26","doi-asserted-by":"crossref","first-page":"L997","DOI":"10.1152\/ajplung.00156.2002","article-title":"Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis","volume":"284","author":"Corvol","year":"2003","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.biopha.2025.118667_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep21465","article-title":"Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections","volume":"6","author":"Cigana","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118667_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12864-015-2276-8","article-title":"Comparative genomics and biological characterization of sequential Pseudomonas aeruginosa isolates from persistent airways infection","volume":"16","author":"Bianconi","year":"2015","journal-title":"BMC Genom."},{"key":"10.1016\/j.biopha.2025.118667_bib29","series-title":"CLSI M100-S24. Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement","author":"CLSI","year":"2014"},{"issue":"7","key":"10.1016\/j.biopha.2025.118667_bib30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"NC3Rs Reporting Guidelines Working Group, Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:51:51Z","timestamp":1777013511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S0753332225008613"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118667","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-inflammatory therapies from bedside to bench: Frameworks to support preclinical development","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118667"}}